Sibutramine use in pregnancy: Report of two cases


Kadioglu M. , ULKU C., YARIS F., Kesim M., Kalyoncu N. İ. , Yaris E.

BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, vol.70, no.8, pp.545-546, 2004 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 8
  • Publication Date: 2004
  • Doi Number: 10.1002/bdra.20052
  • Title of Journal : BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
  • Page Numbers: pp.545-546

Abstract

BACKGROUND: Sibutramine is a drug used for the medical treatment of obesity. No data are available on sibutramine use in pregnancy. We report the fetal outcomes of two pregnant women exposed to sibutramine. CASES: The first woman was exposed to 10 mg/day of sibutramine during gestational weeks 4-6. The second woman was exposed to 10 mg/day of sibutramine during gestational weeks 5-8. At weeks 37 and 39, they delivered healthy infants. CONCLUSIONS: To our knowledge, this is the first report of sibutramine exposure in pregnancy. These cases may contribute to the knowledge about sibutramine use during pregnancy. (C) 2004 Wiley-Liss, Inc.